Cala announced today that it received FDA clearance for its kIQ Plus next-generation wearable neurostimulation device.
The funds from Trinity Capital are expected to advance commercialisation efforts for Cala Health’s device for alleviating ...
The company's FDA-cleared wearable uses personalized nerve stimulation to treat essential tremor and Parkinson's disease.
Trinity Capital announced today that it committed $50 million in growth capital to wearable bioelectronic developer Cala ...
After securing Medicare coverage for its wearable neurostimulator to help people control their hand tremors, Cala Health has raised $50 million to boost its commercial trajectory. The Silicon ...
Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device ...
While many wearable devices currently available to people with Parkinson’s disease focus mainly on tracking the condition, the latest iteration of Cala Health’s externally worn technology is aiming to ...
Cala Health recently published a post-market surveillance study that demonstrates the long-term efficacy of its wrist-based wearable for people with essential tremor, finding that the device reduced ...
Cala has developed a highly efficient and intelligent heat pump system that heats water based on the patterns of hot water use in each home and the preferences of the homeowner. By understanding each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results